Janssen neuroscience leader takes on rare diseases one small ‘eureka’ at a time

Fueled by a fascination with the scientific process, Sindhu Ramchandren is exploring how a new drug could treat patients with a range of rare diseases.

By Michael Gibney • March 9, 2023

Targeting the new ‘Golden Girls’

With unprecedented buying power, women over 50 wield a lot of influence — but are still underserved by pharma. Urovant hopes to change that with its potential blockbuster drug.

By Taren Grom • March 8, 2023

Explore the Trendline➔

Artificial intelligence & machine learning

After years of excited buzz around the potential of artificial intelligence and machine learning, pharma has begun to realize the true implications and potential value of these technologies.

By PharmaVoice staff

Eli Lilly took price cuts into its own hands. Will other pharmas follow suit?

The pharma giant took the high road and cut prices before the feds made them. How will that affect the industry?

By Michael Gibney • March 7, 2023

3 keys to good storytelling in pharma

The CEO of Complement Therapeutics shares simple storytelling tactics lead to maximum impact.

By Alexandra Pecci • March 7, 2023

Why layoffs are not the answer to biopharma’s troubled market

As companies look to cut costs, an EY analyst urges them to consider not cutting staff.

By Kelly Bilodeau • March 6, 2023

FDA ups generics and biosimilar approvals for a shot at lower drug costs

As the Biden administration searched for drug-cost reducing measures, the FDA incentivized generic and biosimilar development in 2022. 

By Karissa Waddick • March 6, 2023

Biosimilar insights to help marketers navigate the year ahead

Bracing for biosimilars? Learn how biosimilar launches differ from traditional biologics.

March 6, 2023

PharmaVoice 100 honorees: Where are they now?

How some of our past PharmaVoice 100 honorees are transforming the life sciences industry in new roles. 

By Taren Grom , Karissa Waddick • March 3, 2023

Do R&D costs justify the price of drugs? Nope, new study says

A BMJ study found that spending on drug sales vastly outstripped spending on drug development.

By Alexandra Pecci • March 1, 2023

Woman of the Week: Denali Therapeutics’ Cindy Dunkle

As chief people officer, Dunkle is harnessing the company’s unique culture to foster innovation.

By Taren Grom • March 1, 2023

Reata’s stock plummets amid sudden FDA neuro office shakeup

The FDA’s longtime neuroscience head Billy Dunn stepped down, leaving industry reeling over how the agency’s new acting director could handle upcoming approval decisions.

By Karissa Waddick • Feb. 28, 2023

As clinical trials face a hiring crunch, here’s how research organizations can pivot

Staffing shortages are causing inefficiencies in clinical trials, but one leading CRO is finding ways to adapt.

By Kelly Bilodeau • Feb. 27, 2023

Why FDA’s approach to orphan drug exclusivity is ripe for more legal challenges

Despite a court ruling, the FDA is sticking to its narrow orphan drug exclusivity approach. But confusion remains over the policy’s future. 

By Karissa Waddick • Feb. 23, 2023

Why patient care is a public affair

The VP of public affairs at Kyowa Kirin discusses her role in advocating for advocacy.

By Taren Grom • Feb. 23, 2023

Woman of the Week: Alltrna’s Michelle Werner

The first-time CEO has her sights on addressing thousands of diseases with the company’s tRNA platform.

By Taren Grom • Feb. 22, 2023

Why the pharma industry is digging deep in rare disease

The rare disease market is set for major growth in the decade to come, and pharma companies are securing their footholds now.

By Michael Gibney • Feb. 21, 2023

Despite rare disease market growth, pharma leaders see development obstacles ahead

Investment in rare disease research is increasing, but a recent poll of PharmaVoice readers found that roadblocks remain.

By Karissa Waddick • Feb. 17, 2023

Marking one year as FDA commissioner, Califf lays out vision for agency’s future

Califf outlined hopes to address advisory committees, drug pricing, digital health and more.

By Karissa Waddick • Feb. 16, 2023

Woman of the Week: Bristol Myers Squibb’s Ester Banque

The 30-year veteran is heading up the “transformation” of one of the pharma giant’s most important therapeutic portfolios: hematology.

By Taren Grom • Feb. 15, 2023

The post-COVID outlook for decentralized clinical trials

The COVID-19 pandemic had many pharmas turning to DCTs as a way to keep the clinical wheel turning. Can the industry keep that flexibility going forward? 

By Michael Gibney • Feb. 14, 2023

For Complement’s CEO, storytelling could be just as critical as data

Dr. Rafiq Hasan has his sights on bringing lessons learned at Bayer to ophthalmology-focused Complement Therapeutics.

By Alexandra Pecci • Feb. 14, 2023

Brian Fox is bringing ‘fresh eyes’ to ad agency Klick

Why the recently appointed president of commercial solutions sees near limitless potential to expand Klick’s footprint across the life sciences — and how generative AI is playing a role.

By Karissa Waddick • Feb. 13, 2023

Why are there gaps in mental healthcare? Often it’s flawed trial methodology

Sunovion Pharmaceuticals has developed a more precise way to track symptoms that could be broadly adopted across the industry.

By Kelly Bilodeau • Feb. 10, 2023

Rocket Pharmaceuticals is ready for liftoff in the rare disease space

With two rare disease products on the launch pad for FDA submission in 2023 and a growing pipeline, Rocket is fueled for its next era of growth.

By Taren Grom • Feb. 10, 2023

Bayer, Astellas switch CEOs amid major inflection points

Bayer’s Bill Anderson and Astellas’ Naoki Okamura will be charged with setting the companies on growth trajectories for 2023.

By Karissa Waddick • Feb. 9, 2023